RARE News and Press, Ultragenyx Pharmaceutical Inc. From 02/16/23

2022 Total Collaboration and Product Revenue of $355.6 million, Crysvita ® revenue of $ 279.4 million and Dojolvi ® revenue of $55.6 million 2023 expected Total Revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 mill...

Ultragenyx Pharmaceutical ( NASDAQ: RARE ) is scheduled to announce Q4 earnings results on Thursday, February 16th, after market close. The consensus EPS Estimate is -$1.80 and the consensus Revenue Estimate is $105.11M (+26.0% Y/Y). Over the last 3 months, EPS estimates have ...

Summary Ultragenyx has been punished on the chart over the past 2 years to date. Investors haven't rewarded the company's top-line growth, nor recognized the potential in its investigational pathways. Despite this, we believe there is scope for the stock to re-rate on the back of it...

NOVATO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on ...

Summary Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality. Fast facts on GNOM. 10 stocks cheaper than their peers in January. This monthly article...

The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with this event. For further details see: Ultragenyx Pharmaceutical (RARE) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow

Ultragenyx Pharmaceutical ( NASDAQ: RARE ) on Friday said it sees total product revenue of $425M-$450M in 2023 with the vast majority of it -- $325M-$340M -- coming from Crysvita (burosumab). The rare diseases focused biotech also sees preliminary 2022 product revenues of $352M-$3...

Preliminary 2022 Total Product Revenue of $352 million to $356 million, Crysvita ® Revenue in Ultragenyx Territories 1 of $257 million to $258 million and Dojolvi ® revenue of $55 million to $56 million 2023 expected Total Product Revenue guidance between $42...

NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the ...

Summary GLPG is setting to transform its business after a slew of failures. The new CEO is a global expert at this, and I don't see him failing. They have a huge cash stockpile. I haven’t covered Galapagos ( GLPG ) in a while. My last coverage of t...